DLA Piper represented SoftBank Vision Fund in leading a $400 million Series C funding round in Zymergen, the world’s first molecular manufacturing technology company.

Zymergen is unleashing biology’s potential for industry. By leveraging advances in artificial intelligence, robotic lab automation, and cutting-edge genomics, Zymergen has unlocked previously inaccessible sources of molecular diversity for critical industries around the world. With its proprietary technology platform, the company makes novel and improved molecules to meet the greatest needs of global leaders in manufacturing, specialty chemicals, food and agriculture, electronics, and pharmaceuticals. Zymergen delivers its customers material diversity and performance capabilities not previously possible by rapidly, reliably, and cost-effectively engineering biology.

The DLA Piper team representing SoftBank Vision Fund was led by partner Louis Lehot and included partner Craig Lang and associate Evan Youngstrom (all of Silicon Valley).